Lancet Reg Health Eur. 2023;33:100706 doi: 10.1016/j.lanepe.2023.100706
Comparing the alignment of European national recommendations for patients with PsA and axSpA with EULAR and ASAS-EULAR treatment recommendations found that only a minority of national treatment recommendations were completely aligned.
Most countries establish their own national treatment recommendations for PsA and axSpA, which overlap to varying degrees with international recommendations. However, such national recommendations could potentially result in heterogeneity across countries in terms of eligibility criteria for treatment and available treatment options.
Michelsen, et al. used electronic records to examine differences and similarities between the most recent EULAR and ASAS-EULAR recommendations for the treatment of PsA and axSpA, respectively, and the most recent national PsA and axSpA treatment recommendations from countries within the EuroSpA RCN.